S100A4 and neoplasm: Further, S100A4 is capable of activating the phosphoinositide 3-kinase/Akt/mechanistic target of the rapamycin pathway (PI3K/Akt/mTOR), leading to increased levels of VEGF and decreased E-cadherin, which triggers tumour progression and cell migration [161].